Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (121-130 of 222) with videos related to

Pageof 23
Sort By:
BMC Dermatology|October 8, 2016
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trialKim A Papp, Robert Bissonnette, Melinda Gooderham, et al.
The Journal of Investigative Dermatology|June 28, 2017
Response to Hjuler et alRobert Bissonnette, François Harel, James G Krueger, et al.
The Journal of Investigative Dermatology|March 14, 2017
TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled StudyRobert Bissonnette, François Harel, James G Krueger, et al.
Journal of Drugs in Dermatology : JDD|October 17, 2017
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With PsoriasisRobert Bissonnette, Francisco Kerdel, Luigi Naldi, et al.
Eclinicalmedicine|February 23, 2023
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a studyHoward Sofen, Robert Bissonnette, Gil Yosipovitch, et al.
The New England Journal of Medicine|February 7, 2024
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque PsoriasisRobert Bissonnette, Andreas Pinter, Laura K Ferris, et al.
The Journal of Investigative Dermatology|February 1, 2021
Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. SecukinumabHeena Mehta, Shunya Mashiko, Julianty Angsana, et al.
Journal of Cutaneous Medicine and Surgery|November 19, 2010
Canadian hand dermatitis management guidelinesCharles Lynde, Lyn Guenther, Thomas L Diepgen, et al.
The Journal of Allergy and Clinical Immunology|March 18, 2020
ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammationJuan Manuel Leyva-Castillo, Claire Galand, Shunya Mashiko, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital PsoriasisJoseph F Merola, Alison Potts Bleakman, Alice B Gottlieb, et al.
Pageof 23

Showing results (121-130 of 222) with videos related to

Sort By:
Pageof 23
BMC Dermatology|October 8, 2016
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trialKim A Papp, Robert Bissonnette, Melinda Gooderham, et al.
The Journal of Investigative Dermatology|June 28, 2017
Response to Hjuler et alRobert Bissonnette, François Harel, James G Krueger, et al.
The Journal of Investigative Dermatology|March 14, 2017
TNF-α Antagonist and Vascular Inflammation in Patients with Psoriasis Vulgaris: A Randomized Placebo-Controlled StudyRobert Bissonnette, François Harel, James G Krueger, et al.
Journal of Drugs in Dermatology : JDD|October 17, 2017
Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With PsoriasisRobert Bissonnette, Francisco Kerdel, Luigi Naldi, et al.
Eclinicalmedicine|February 23, 2023
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a studyHoward Sofen, Robert Bissonnette, Gil Yosipovitch, et al.
The New England Journal of Medicine|February 7, 2024
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque PsoriasisRobert Bissonnette, Andreas Pinter, Laura K Ferris, et al.
The Journal of Investigative Dermatology|February 1, 2021
Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. SecukinumabHeena Mehta, Shunya Mashiko, Julianty Angsana, et al.
Journal of Cutaneous Medicine and Surgery|November 19, 2010
Canadian hand dermatitis management guidelinesCharles Lynde, Lyn Guenther, Thomas L Diepgen, et al.
The Journal of Allergy and Clinical Immunology|March 18, 2020
ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammationJuan Manuel Leyva-Castillo, Claire Galand, Shunya Mashiko, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital PsoriasisJoseph F Merola, Alison Potts Bleakman, Alice B Gottlieb, et al.
Pageof 23